CA2186987A1 - Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete - Google Patents

Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete

Info

Publication number
CA2186987A1
CA2186987A1 CA002186987A CA2186987A CA2186987A1 CA 2186987 A1 CA2186987 A1 CA 2186987A1 CA 002186987 A CA002186987 A CA 002186987A CA 2186987 A CA2186987 A CA 2186987A CA 2186987 A1 CA2186987 A1 CA 2186987A1
Authority
CA
Canada
Prior art keywords
core
glcnac
g1cnac
substance
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002186987A
Other languages
English (en)
Inventor
George L. King
James W. Dennis
Charles E. Warren
Daleuke Koya
Yoshihiko Nishio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Priority to CA002186987A priority Critical patent/CA2186987A1/fr
Publication of CA2186987A1 publication Critical patent/CA2186987A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0362Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002186987A 1996-10-02 1996-10-02 Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete Abandoned CA2186987A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002186987A CA2186987A1 (fr) 1996-10-02 1996-10-02 Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002186987A CA2186987A1 (fr) 1996-10-02 1996-10-02 Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete

Publications (1)

Publication Number Publication Date
CA2186987A1 true CA2186987A1 (fr) 1998-04-02

Family

ID=4159008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186987A Abandoned CA2186987A1 (fr) 1996-10-02 1996-10-02 Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete

Country Status (1)

Country Link
CA (1) CA2186987A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131334A1 (fr) * 1998-11-21 2001-09-12 The Regents of the University of California Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation
WO2005060977A1 (fr) * 2003-12-22 2005-07-07 Btg International Limited Inhibiteurs de la glcnac-t de structure noyau 2
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
US7811781B2 (en) 2005-07-06 2010-10-12 Btg International Limited Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US20140228313A1 (en) * 2005-01-14 2014-08-14 The Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131334A1 (fr) * 1998-11-21 2001-09-12 The Regents of the University of California Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation
EP1131334A4 (fr) * 1998-11-21 2003-05-21 Univ California Utilisation d'inhibiteurs de 2 glcnac transferase centrale dans le traitement d'inflammation
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
WO2005060977A1 (fr) * 2003-12-22 2005-07-07 Btg International Limited Inhibiteurs de la glcnac-t de structure noyau 2
JP2007515466A (ja) * 2003-12-22 2007-06-14 ビーティージー・インターナショナル・リミテッド コア2GlcNAc−T阻害剤
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US20140228313A1 (en) * 2005-01-14 2014-08-14 The Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
US9775859B2 (en) * 2005-01-14 2017-10-03 Sinai Health System Methods and compositions for preventing and treating a disease related to glycan dysregulation
US7811781B2 (en) 2005-07-06 2010-10-12 Btg International Limited Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors

Similar Documents

Publication Publication Date Title
Nishio et al. Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue.
US6436908B1 (en) Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
Takahashi et al. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca (2+)-ATPase gene.
Altomonte et al. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice
KR20190087673A (ko) Gla 유전자에 g9331a 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
Teshigawara et al. Role of Krüppel-like factor 15 in PEPCK gene expression in the liver
WO2006056885A2 (fr) Nouveaux peptides igf-i
WO2006137597A1 (fr) Substance physiologique innovante nesfatine, substance qui lui est liée et utilisation des substances
CA2186987A1 (fr) Inhibiteurs de glcnac-t et leur emploi pour prevenir ou traiter la cardiomyopathie associee au diabete
US20030022241A1 (en) Methods
US6131578A (en) Inhibitors of UDP-G1cNAc:Ga1β1-3Ga1NAcαR β1-6 N-acetylglucosaminyltransferase (core 2 G1cNAc-T) and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes
EP2612678B1 (fr) Méthode de criblage d'agent antidiabétique utilisant un facteur de régulation de la sécrétion d'insuline
US20100076059A1 (en) METHOD OF EVALUATING COMPOUND EFFICACIOUS IN TREATING OBESITY BY USING Slc25a10
JP2000514422A (ja) 肥満のための遺伝子治療
US7160859B2 (en) Mst1 modulation of apoptosis in cardiac tissue and modulators of Mst1 for treatment and prevention of cardiac disease
WO2007102572A1 (fr) Inhibiteur de vieillissement cellulaire
US7091018B2 (en) Enzyme gene and its expression product
PT90019B (pt) Processo para a preparacao e purificacao de factor de choque termico humano
US20040014055A1 (en) Gene coding for erbin, and diagnostic and therapeutic uses thereof
US20070231812A1 (en) Method of Screening Antidiabetic Agents
JP4264904B2 (ja) 糖尿病改善薬のスクリーニングに利用できる新規蛋白質
KR100394387B1 (ko) 세포 성장 억제 및 세포 분화 특이적인 지에이디디45감마유전자의 게놈 디엔에이 염기 서열 및 그것의 프로모터
Rogatcheva et al. Type 1 iodothyronine deiodinase in the house musk shrew (Suncus murinus, Insectivora: Soricidae): cloning and characterization of complementary DNA, unique tissue distribution and regulation by T3
Berman et al. Metabolic mechanisms and diabetes candidate genes: insights gained from genetic engineering with recombinant adenoviruses
JPWO2005093068A1 (ja) 新規タンパク質及びプロモーター

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued